Circulatory 25(OH)D and 1,25(OH)2D as differential biomarkers between multiple system atrophy and Parkinson's disease patients
Background and purpose: There is sufficient evidence to support vitamin D's noncalcemic effects and the role of vitamin D deficiency in the development of a wide range of neurological disorders. This study aimed to evaluate whether serum 25(OH)D and 1,25(OH) 2 D could be used as biomarkers to d...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-12-01
|
| Series: | eNeurologicalSci |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405650221000617 |
| _version_ | 1818873668596400128 |
|---|---|
| author | Hiromu Ogura Izzettin Hatip-Al-Khatib Midori Suenaga Funda Bolukbasi Hatip Takayasu Mishima Shinsuke Fujioka Shinji Ouma Yoichi Matsunaga Yoshio Tsuboi |
| author_facet | Hiromu Ogura Izzettin Hatip-Al-Khatib Midori Suenaga Funda Bolukbasi Hatip Takayasu Mishima Shinsuke Fujioka Shinji Ouma Yoichi Matsunaga Yoshio Tsuboi |
| author_sort | Hiromu Ogura |
| collection | DOAJ |
| description | Background and purpose: There is sufficient evidence to support vitamin D's noncalcemic effects and the role of vitamin D deficiency in the development of a wide range of neurological disorders. This study aimed to evaluate whether serum 25(OH)D and 1,25(OH) 2 D could be used as biomarkers to differentiate between healthy subjects (HS), multiple system atrophy (MSA) and Parkinson's disease (PD) patients of both genders. Methods: A total of 107 subjects were included in this study, divided into three groups: 1- HS (n = 61), 2- MSA patients (n = 19), and 3- PD patients (n = 27). The patients were assessed using UMSARS II, UPDRS III, H&Y, MMSE and MoCA rating scales. The levels of 25(OH)D and 1,25(OH) 2 D in serum were determined using the radioimmunoassay technique. Results: The levels of 25(OH)D and 1,25(OH) 2 D in HS were 26.85 +/− 7.62 ng/mL and 53.63 +/− 13.66 pg/mL respectively. 25(OH)D levels were lower in both MSA and PD by 61% and 50%, respectively (P = 0.0001 vs. HS). 1,25(OH) 2 D levels were lower in MSA by 29%(P = 0.001 vs HS). There was a correlation between 25(OH)D and 1,25(OH) 2 D in MSA and PD, but not in HS. 1,25(OH) 2 D regressed with MMSE (β = 0.476, P = 0.04, R 2 = 0.226) in MSA, and with UPDRS III (β = −0.432, P = 0.024, R 2 = 0.187) and MoCA (β = 0.582, P = 0.005,R 2 = 0.279) in PD. 25(OH)D displayed considerable differentiative strength between HS and MSA (Wald = 17.123, OR = 0.586, P = 0.0001; AUC = 0.982, sensitivity and Youden index = 0.882, P = 0.0001) and PD (Wald = 18.552, OR = 0.700, P = 0.0001; AUC = 0.943, sensitivity = 0.889, YI = 0.791, P = 0.0001). 1,25(OH) 2 D distinguished MSA from PD (Wald 16.178, OR = 1.117, P = 0.0001; AUC = 0.868, sensitivity = 0.926, Youden index =0.632, P = 0.0001). H&Y exhibited the highest sensitivity, AUC, and significant distinguishing power between MSA and PD. Conclusions: Serum 25(OH)D and 1,25(OH) 2 D could be useful biomarkers for MSA and PD. 25(OH)D and H&Y provided the highest sensitivity and group classification characteristics. |
| first_indexed | 2024-12-19T12:58:22Z |
| format | Article |
| id | doaj.art-a0cf07f66a574b91bf8d9bd56685ae70 |
| institution | Directory Open Access Journal |
| issn | 2405-6502 |
| language | English |
| last_indexed | 2024-12-19T12:58:22Z |
| publishDate | 2021-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | eNeurologicalSci |
| spelling | doaj.art-a0cf07f66a574b91bf8d9bd56685ae702022-12-21T20:20:20ZengElseviereNeurologicalSci2405-65022021-12-0125100369Circulatory 25(OH)D and 1,25(OH)2D as differential biomarkers between multiple system atrophy and Parkinson's disease patientsHiromu Ogura0Izzettin Hatip-Al-Khatib1Midori Suenaga2Funda Bolukbasi Hatip3Takayasu Mishima4Shinsuke Fujioka5Shinji Ouma6Yoichi Matsunaga7Yoshio Tsuboi8Department of Neurology, Faculty of Medicine, Fukuoka University, Fukuoka, JapanDepartment of Medical Pharmacology, Faculty of Medicine, Pamukkale University, Denizli, TurkeyDepartment of Medical Pharmacology, Faculty of Pharmaceutical Sciences, Tokushima-Bunri University, Tokushima, JapanDepartment of Medical Pharmacology, Faculty of Medicine, Pamukkale University, Denizli, TurkeyDepartment of Neurology, Faculty of Medicine, Fukuoka University, Fukuoka, JapanDepartment of Neurology, Faculty of Medicine, Fukuoka University, Fukuoka, JapanDepartment of Neurology, Faculty of Medicine, Fukuoka University, Fukuoka, JapanDepartment of Neurology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan; Corresponding author at: Department of Neurology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.Department of Neurology, Faculty of Medicine, Fukuoka University, Fukuoka, JapanBackground and purpose: There is sufficient evidence to support vitamin D's noncalcemic effects and the role of vitamin D deficiency in the development of a wide range of neurological disorders. This study aimed to evaluate whether serum 25(OH)D and 1,25(OH) 2 D could be used as biomarkers to differentiate between healthy subjects (HS), multiple system atrophy (MSA) and Parkinson's disease (PD) patients of both genders. Methods: A total of 107 subjects were included in this study, divided into three groups: 1- HS (n = 61), 2- MSA patients (n = 19), and 3- PD patients (n = 27). The patients were assessed using UMSARS II, UPDRS III, H&Y, MMSE and MoCA rating scales. The levels of 25(OH)D and 1,25(OH) 2 D in serum were determined using the radioimmunoassay technique. Results: The levels of 25(OH)D and 1,25(OH) 2 D in HS were 26.85 +/− 7.62 ng/mL and 53.63 +/− 13.66 pg/mL respectively. 25(OH)D levels were lower in both MSA and PD by 61% and 50%, respectively (P = 0.0001 vs. HS). 1,25(OH) 2 D levels were lower in MSA by 29%(P = 0.001 vs HS). There was a correlation between 25(OH)D and 1,25(OH) 2 D in MSA and PD, but not in HS. 1,25(OH) 2 D regressed with MMSE (β = 0.476, P = 0.04, R 2 = 0.226) in MSA, and with UPDRS III (β = −0.432, P = 0.024, R 2 = 0.187) and MoCA (β = 0.582, P = 0.005,R 2 = 0.279) in PD. 25(OH)D displayed considerable differentiative strength between HS and MSA (Wald = 17.123, OR = 0.586, P = 0.0001; AUC = 0.982, sensitivity and Youden index = 0.882, P = 0.0001) and PD (Wald = 18.552, OR = 0.700, P = 0.0001; AUC = 0.943, sensitivity = 0.889, YI = 0.791, P = 0.0001). 1,25(OH) 2 D distinguished MSA from PD (Wald 16.178, OR = 1.117, P = 0.0001; AUC = 0.868, sensitivity = 0.926, Youden index =0.632, P = 0.0001). H&Y exhibited the highest sensitivity, AUC, and significant distinguishing power between MSA and PD. Conclusions: Serum 25(OH)D and 1,25(OH) 2 D could be useful biomarkers for MSA and PD. 25(OH)D and H&Y provided the highest sensitivity and group classification characteristics.http://www.sciencedirect.com/science/article/pii/S2405650221000617Parkinson's diseaseMultiple system atrophyVitamin DUnified PD rating scaleUnified MSA rating scaleHoehn & Yahr staging scale |
| spellingShingle | Hiromu Ogura Izzettin Hatip-Al-Khatib Midori Suenaga Funda Bolukbasi Hatip Takayasu Mishima Shinsuke Fujioka Shinji Ouma Yoichi Matsunaga Yoshio Tsuboi Circulatory 25(OH)D and 1,25(OH)2D as differential biomarkers between multiple system atrophy and Parkinson's disease patients eNeurologicalSci Parkinson's disease Multiple system atrophy Vitamin D Unified PD rating scale Unified MSA rating scale Hoehn & Yahr staging scale |
| title | Circulatory 25(OH)D and 1,25(OH)2D as differential biomarkers between multiple system atrophy and Parkinson's disease patients |
| title_full | Circulatory 25(OH)D and 1,25(OH)2D as differential biomarkers between multiple system atrophy and Parkinson's disease patients |
| title_fullStr | Circulatory 25(OH)D and 1,25(OH)2D as differential biomarkers between multiple system atrophy and Parkinson's disease patients |
| title_full_unstemmed | Circulatory 25(OH)D and 1,25(OH)2D as differential biomarkers between multiple system atrophy and Parkinson's disease patients |
| title_short | Circulatory 25(OH)D and 1,25(OH)2D as differential biomarkers between multiple system atrophy and Parkinson's disease patients |
| title_sort | circulatory 25 oh d and 1 25 oh 2d as differential biomarkers between multiple system atrophy and parkinson s disease patients |
| topic | Parkinson's disease Multiple system atrophy Vitamin D Unified PD rating scale Unified MSA rating scale Hoehn & Yahr staging scale |
| url | http://www.sciencedirect.com/science/article/pii/S2405650221000617 |
| work_keys_str_mv | AT hiromuogura circulatory25ohdand125oh2dasdifferentialbiomarkersbetweenmultiplesystematrophyandparkinsonsdiseasepatients AT izzettinhatipalkhatib circulatory25ohdand125oh2dasdifferentialbiomarkersbetweenmultiplesystematrophyandparkinsonsdiseasepatients AT midorisuenaga circulatory25ohdand125oh2dasdifferentialbiomarkersbetweenmultiplesystematrophyandparkinsonsdiseasepatients AT fundabolukbasihatip circulatory25ohdand125oh2dasdifferentialbiomarkersbetweenmultiplesystematrophyandparkinsonsdiseasepatients AT takayasumishima circulatory25ohdand125oh2dasdifferentialbiomarkersbetweenmultiplesystematrophyandparkinsonsdiseasepatients AT shinsukefujioka circulatory25ohdand125oh2dasdifferentialbiomarkersbetweenmultiplesystematrophyandparkinsonsdiseasepatients AT shinjiouma circulatory25ohdand125oh2dasdifferentialbiomarkersbetweenmultiplesystematrophyandparkinsonsdiseasepatients AT yoichimatsunaga circulatory25ohdand125oh2dasdifferentialbiomarkersbetweenmultiplesystematrophyandparkinsonsdiseasepatients AT yoshiotsuboi circulatory25ohdand125oh2dasdifferentialbiomarkersbetweenmultiplesystematrophyandparkinsonsdiseasepatients |